OBR Daily Commentary - ASCO Conference Coverage

forumImage

Pembrolizumab Increases Historic Survival Rate for Certain People with Advanced Non-Small Cell Lung Cancer

(2019 ASCO) June 1, 2019 – Five-year data from the phase Ib KEYNOTE-001 clinical trial show that pembrolizumab (Keytruda) was safe and effective and substantially increased overall survival for advanced non-small cell lung cancer (aNSCLC). Specifically, 23.2% of people who had not previously been treated with chemotherapy and 15.5% of previously-treated patients were alive after five years, with the greatest benefit observed in patients with higher PD-L1 expression. This represents a marked improvement over 5-year survival rates from the pre-immunotherapy era, which averaged 5.5% for aNSCLC. This is the longest follow-up study to date of people with aNSCLC treated with pembrolizumab, according to the researchers.

H. Jack West, MD (Posted: June 05, 2019)

quotesWhile in keeping with what we see informally in our clinics, these documented results from primarily previously treated patients a trial setting highlight the amazing advance that PD1/PD-L1 directed immunotherapy represents in NSCLC. We are seeing a significant minority of our patients alive 5 years out from starting a salvage therapy, and even 25% of patients with high tumor PD-L1 (50% or higher); many are without evidence of active disease. It is truly remarkable, though the fact that there are clear differences based on PD-L1 expression highlight that there are still some patients who are much more or less likely to be major beneficiaries.quotes

Read Article arrow
Add Comment 1 Comment
forumImage

ERLEADA®(apalutamide) Significantly Improved Overall Survival and Radiographic Progression-Free Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer

(J&J) May 31, 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today findings from the investigational Phase 3 TITAN study, which showed the addition of ERLEADA® (apalutamide) to androgen deprivation therapy (ADT) compared with placebo plus ADT significantly improved the dual primary endpoints of overall survival (OS) and radiographic progression-free survival (rPFS) in patients with metastatic castration-sensitive prostate cancer (mCSPC). The study included patients with mCSPC regardless of extent of disease or prior docetaxel treatment history.1 Results were presented in an oral session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (abstract #5006), and simultaneously published online in The New England Journal of Medicine. The data were selected for the Best of ASCO 2019 Meetings, which highlight cutting-edge science and reflect leading research in oncology.

Tomasz M. Beer, MD, FACP (Posted: June 01, 2019)

quotesThe TITAN study adds apalutamide to a growing number of agents that improve outcomes in metastatic prostate cancer. It is now crystal clear that the first treatment for metastatic prostate cancer must include more than standard hormonal agents like leuprolide. Which agent to add, be it apalutamide, enzalutamide, abiraterone, or docetaxel, is a decision each patient and their oncologist will make. But conventional ADT alone is clearly inferior.quotes

Read Article arrow
Add Comment 1 Comment
forumImage

MacroGenics Thrives Following Positive Breast Cancer Results

(BioSpace) May 16, 2019 - The trial evaluated margetuximab in patients with HER2-positive metastastic breast cancer who had already been treated with anti-HER2-targeted therapies.

(Posted: May 17, 2019)

quotesTrastuzumab deruxtecan makes Margetixumab clinically irrelevant quotes

Read Article arrow
Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...